Baheal Pharmaceutical released its 2026 semi-annual report. In the first half of the year, it achieved operating revenue of 3.56 billion yuan, or 4.068 billion yuan after restating for the two-invoice system. Net profit attributable to the parent company was 225 million yuan, up 37.72% year-on-year, while non-GAAP net profit attributable to the parent company was 221 million yuan, up 24.58%. The company continued to optimize its product mix and focus on its own-brand operations. Brand operation revenue reached 2.722 billion yuan, with a gross margin of 48.59%, and gross profit from this segment accounted for 93.27% of the total. The core product, the ZAP-X radiosurgery robot, has been approved for market in 26 countries and regions worldwide, with over 8,100 clinical applications, and the company plans to mass-produce 18 units in 2026. In innovative drugs, the Class 1 innovative radiopharmaceutical Gilunte has been approved for market, and multiple pipeline projects have entered the clinical stage.
Qingdao Baheal Medical INC.Net profit up 37.72% and revenue growth reported in semi-annual results.
